Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_1
3
38%
Ph phase_2
2
25%
Ph not_applicable
1
13%
Ph early_phase_1
1
13%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
2(28.6%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(2)
Other(1)

Detailed Status

Completed5
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
71.4%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (14.3%)
Phase 13 (42.9%)
Phase 22 (28.6%)
N/A1 (14.3%)

Trials by Status

completed563%
unknown113%
terminated225%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_2

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

NCT01118351
completedearly_phase_1

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

NCT00757549
completedphase_1

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

NCT00379509
completed

Study of Proteins in Head and Neck Cancer Cells

NCT00896948
terminatedphase_2

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

NCT01316692
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01118351Phase 2

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Terminated
NCT00757549Early Phase 1

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

Completed
NCT00379509Phase 1

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

Completed
NCT00896948

Study of Proteins in Head and Neck Cancer Cells

Completed
NCT01316692Phase 2

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

Terminated
NCT00714181Phase 1

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed
NCT00550784Phase 1

Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Completed
NCT00671476Not Applicable

Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery

Unknown

All 8 trials loaded

Drug Details

Intervention Type
GENETIC
Total Trials
8